Navigation Links
Plandai Biotechnology, Inc. Announces Formation Of New Entity To Develop Pharmaceutical Applications
Date:5/7/2013

SEATTLE, May 7, 2013 /PRNewswire/ -- Plandai Biotechnology, Inc. (OTCQB: PLPL), a producer of highly bioavailable plant extracts for industries including health, wellness, nutraceutical, and pharmaceutical, today announced the formation of Phyto Pharmacare, Inc., a Delaware corporation, which will oversee all aspects of developing and marketing Phytofare™ extracts for pharmaceutical and drug applications.

Plandai Chief Executive Officer Roger Duffield commented, "As a management team, we felt it necessary to differentiate the purely pharmaceutical operations from our farming, production and nutraceutical business. Taking our Phytofare™ extracts and seeking FDA clearance to market them to treat specific diseases brings unique challenges and requires an entirely different focus. The creation of Phyto Pharmacare, which will operate under a license from Plandai, enables that division to focus on specific drug targets and take our products through the various stages of clinical trials and FDA approval."

Initially, Phyto Pharmacare will focus on using its Phytofare™ Catechin Extract as both a cure for and prevention of malaria.  Malaria is a parasite infection transmitted by mosquitoes and primarily located in sub-Sahara Africa and southern Asia, where it results in nearly a million deaths annually. 

Mr. Duffield explained, "Malaria is one of great plagues that still kills way too many people, most of whom are children and the elderly located in some of the poorest and most remote areas of the world where access to life-saving medicine is either unaffordable or unavailable.  With drug-resistant strains of the parasite now spreading across Asia, we could soon be facing a pandemic.  The catechins found in green tea are well documented for their anti-malarial properties, but low h
'/>"/>

SOURCE Plandai Biotechnology, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. AMRI Announces First Quarter 2013 Results and Raises EPS Guidance for the Year
2. Rigel Announces First Quarter 2013 Financial Results
3. Mindray Announces First Quarter 2013 Financial Results
4. Lilly Announces CEO Dr. John Lechleiter to Undergo Scheduled Surgery
5. Hologic Announces Second Quarter Fiscal 2013 Operating Results
6. Array Announces Global Phase 3 Trial Evaluating MEK162 In Patients With Low-Grade Serous Ovarian Cancer
7. AG Mednet Announces Partnership with The Methodist DeBakey Heart & Vascular Center Echocardiography Core Lab
8. Isis Pharmaceuticals Announces the Initiation of a Clinical Study of ISIS-STAT3 Rx in Patients with Liver Cancer
9. Apollo Medical Holdings Announces Record Fiscal Year-End Results
10. Atrium Medical Announces 1-year results of the INFUSE-AMI Trial
11. Premier Home Medical Supply Vendor Med Supply Shop Announces Drive Spring Promotion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)...  ArmaGen, Inc., a privately held biotechnology company ... neurological disorders, announced today that the first patient ... clinical trial of AGT-181 in patients with attenuated ... AGT-181 is an investigational enzyme replacement therapy (ERT) ... severe form of MPS I, Hurler syndrome, is ...
(Date:9/2/2015)... 2015  Aethlon Medical, Inc. (Nasdaq: AEMD ), today ... be presenting at the Rodman & Renshaw 17th Annual Global ... at 9:35 a.m. ET on Thursday, September 10, 2015. ... via live audio webcast which can be accessed by visiting ... http://www.aethlonmedical.com . The webcast will be archived for thirty ...
(Date:9/2/2015)... , Sept. 2, 2015  RegeneRx Biopharmaceuticals, Inc. ... drug development company focused on tissue protection, repair ... , President and Chief Executive Officer, will present ... Global Investment Conference, sponsored by H.C. Wainwright ... September 8-10, 2015 at the St. Regis Hotel ...
Breaking Medicine Technology:ArmaGen Announces First Patient Dosed in Phase 1/2a Clinical Trial of AGT-181 for the Treatment of Hurler Syndrome 2ArmaGen Announces First Patient Dosed in Phase 1/2a Clinical Trial of AGT-181 for the Treatment of Hurler Syndrome 3ArmaGen Announces First Patient Dosed in Phase 1/2a Clinical Trial of AGT-181 for the Treatment of Hurler Syndrome 4RegeneRx to Present at Rodman & Renshaw Global Investment Conference 2RegeneRx to Present at Rodman & Renshaw Global Investment Conference 3
(Date:9/2/2015)... Fredericksburg, VA (PRWEB) , ... September 02, 2015 ... ... integrator of document imaging, content, records and case management solutions and services to ... of PurePAGE®, its Image Re-sizing and Image Clean-up utility for IBM’s Datacap document ...
(Date:9/2/2015)... ... September 02, 2015 , ... On September 9, 2015, over 27,000 people from ... largest single-company convention to date for the state of Utah. , “We are thrilled ... event,” states David Stirling, doTERRA CEO. “One of the most exciting elements of our ...
(Date:9/2/2015)... ... ... “ G-Hold ” was featured on NewsWatch as part of its monthly Tech Report, ... technology expert and special reporter for NewsWatch, conducted the review and shared with viewers ... the likelihood of it dropping. , Tablets like the iPad and Samsung Galaxy Tab ...
(Date:9/2/2015)... ... 2015 , ... The payroll conference theme this year is ... covering legislative updates, including unemployment, global payroll best practices, and the latest trends ... Software, the American Payroll Association, Barnett Associates, and the IRS, will keep payroll ...
(Date:9/2/2015)... ... September 02, 2015 , ... Pentec Health, Inc., a national leader ... for an impressive sixth consecutive year. Less than 5 % of this year’s 5000 ... the “health” sector. Pentec’s 3-year revenue growth rate of 65% sustained its most ...
Breaking Medicine News(10 mins):Health News:EDAC Systems, Inc. announces a new version of its Image Enhancement and Image Re-Sizing utility EDAC’s PurePAGE® 2Health News:EDAC Systems, Inc. announces a new version of its Image Enhancement and Image Re-Sizing utility EDAC’s PurePAGE® 3Health News:doTERRA to Host the Largest Single-Company Convention in the State of Utah 2Health News:Comfortably Hold a Tablet with G-Hold Hands Free Tablet Holder 2Health News:23rd Annual NJ Statewide Payroll Conference in Vernon, NJ at the Minerals Hotel on October 15-16, 2015 2Health News:Pentec Health Once Again Named One of the Fastest-Growing Private Companies in America 2
... If the man who mowed down 32 persons at Virginia Tech ... you call the man who has devised a computer game ... rampage, players control an image of Korean-born gunman Cho Seung-hui. Screams ... the other characters. ,21-year-old Ryan Lambourn, an Australian, ...
... reward the federal government with their vote at the next ... the same time he concedes that two bad post-budget polls ... ,"I'm confident that come Election Day, people will reward ... Abbott was quoted. He said he was confident voters had ...
... extended time are the most common but contentious accommodation ... and/or AD/HD taking college entrance and licensing exams. According ... Practice, students given extra time respond to exams similarly ... ,According to my research, there is no real evidence ...
... Director-General of the World Health Organization, has called upon all member ... that would handicap the organization in the fight contain bird blu. ... . I would fail you," said he said in a speech ... countries, Chan said that "you are tying my hands, you're muffling ...
... past, the newborns umbilical cord was not clamped right ... naturally. This practice , known as late clamping, was ... immediately after the infant is expelled. However, this new ... studies on the importance of when clamping should be ...
... on animals, conducted by the National Toxicology Program (NTP), ... as hexavalent chromium (chromium 6) causes cancer when ... ,Hexavalent chromium compounds are often used in electroplating, leather ... some drinking water sources. ,The two-year study ...
Cached Medicine News:Health News:Australian Devises Online Game Based on Virginia Tech Shootout 2Health News:Tony Abbott Confident Of Australias Vote For Performance Not Promise 2Health News:WHO Director Urges Nations to Share Bird Flu Virus Strains 2Health News:Late Clamping of Umbilical Cord may Reduce Anemia in Children 2Health News:Late Clamping of Umbilical Cord may Reduce Anemia in Children 3
Coat-A-Count PAP IRMA,is an immunoradiometric assay designed,for the quantitative measurement of,prostatic acid phosphatase (PAP) in,serum. It is intended strictly for in vitro,diagnostic u...
For in vitro diagnostic use,with the IMMULITE 2000 Analyzer for,the quantitative measurement of prostatic,acid phosphatase (PAP) in serum, as an,aid in patient management....
Abbott offers an array of both in-vitro and molecular diagnostic tests for the detection and monitoring of cancerous conditions in patients....
For the quantitative measurement of human prostatic acid phosphatase (PAP) in human serum....
Medicine Products: